Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps are being taken to ensure that brain tumour patients have equality of access to 5-ALA across all health boards.

In May 2019, the Government announced that the fluorescent dye 5-AminoLevulinic Acid (5-ALA) was being used in all 27 neurological units in the National Health Service in England, in accordance with the National Institute for Health and Care Excellence’s guidelines. Each of England’s neurosurgical units is expected to have an average of around 55 patients requiring 5-ALA per year.